---
trial_id: 251
discovery_date: 2022-03-29 21:28:27.944209
date: 2022-03-29 21:28:27.944209
title: "AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS"
summary: |
  <p>EudraCT Number: 2017-001313-93<br />Sponsor Protocol Number: MN39159<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2018-05-03<br />Medical condition: Progressive multiple sclerosis (PMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IE">IE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DE">DE</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001313-93'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2017-001313-93<br />Sponsor Protocol Number: MN39159<br />Sponsor Name: F. Hoffmann-La Roche Ltd<br />Start Date: 2018-05-03<br />Medical condition: Progressive multiple sclerosis (PMS)<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10053395<br />Term: Progressive multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IE">IE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/ES">ES</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/HU">HU</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/IT">IT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001313-93/DE">DE</a> (Ongoing)</p>